Adaptin Bio (APTN) Return on Equity (2023 - 2026)

Adaptin Bio's Return on Equity history runs 4 years deep, the most recent figure standing at 0.04% for Q1 2026.

• In Q1 2026, Return on Equity rose 1.0% year-over-year to 0.04%; the TTM figure through Mar 2026 stood at 0.04% (up 1.0% YoY), while the FY2025 annual figure was 0.02%, up 1.0% from the prior year.
• Return on Equity came in at 0.04% for Q1 2026 at Adaptin Bio, down from 0.04% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.23% in Q3 2025 to a low of 0.04% in Q2 2025.
• A 4-year average of 0.03% and a median of 0.01% in 2024 frame the typical range for Return on Equity.
• On a YoY basis, Return on Equity climbed as much as 22 bps in 2025 and fell as far as 4 bps in 2025.
• Adaptin Bio's Return on Equity stood at 0.0% in 2023, then soared by 483 bps to 0.01% in 2024, then soared by 416 bps to 0.04% in 2025, then retreated by 20 bps to 0.04% in 2026.
• According to Business Quant data, Return on Equity over the past three periods registered 0.04%, 0.04%, and 0.23% for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison